共 49 条
- [45] Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1 DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 217
- [49] Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician's choice chemotherapy (PCT) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial ANNALS OF ONCOLOGY, 2021, 32 : S480 - S480